Clinical Trial Update: CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study of CD19-directed CAR T cells in patients with resistant or refractory CD19-positive acute lymphoblastic leukemia has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• CD19 CAR T cells

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukaemia Recurrent | Phase 1 | Status: COMPLETED